These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 16943794

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63. Oral tadalafil in pulmonary artery hypertension: a prospective study.
    Aggarwal P, Patial RK, Negi PC, Marwaha R.
    Indian Heart J; 2007; 59(4):329-35. PubMed ID: 19126938
    [Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65. New immunophenotype of circulating endothelial progenitor cells and endothelial microparticles in patients with erectile dysfunction and metabolic syndrome: effects of tadalafil administration.
    La Vignera S.
    Int Angiol; 2011 Oct; 30(5):415-23. PubMed ID: 21804479
    [Abstract] [Full Text] [Related]

  • 66. Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study.
    Greco EA, Pili M, Bruzziches R, Corona G, Spera G, Aversa A.
    J Sex Med; 2006 Jul; 3(4):716-722. PubMed ID: 16839328
    [Abstract] [Full Text] [Related]

  • 67. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
    Fusco F, Razzoli E, Imbimbo C, Rossi A, Verze P, Mirone V.
    BJU Int; 2010 Jun; 105(12):1634-9. PubMed ID: 20553468
    [Abstract] [Full Text] [Related]

  • 68. Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil.
    Paduch DA, Bolyakov A, Beardsworth A, Watts SD.
    BJU Int; 2012 Apr; 109(7):1060-7. PubMed ID: 21883853
    [Abstract] [Full Text] [Related]

  • 69.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS.
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Evaluation of the efficacy of once-daily use of tadalafil vs. on-demand use. Is there a cumulative effect?
    Jamshidian H, Borhan A, Kooraki S, Borhan A.
    J Pak Med Assoc; 2012 Nov; 62(11):1195-8. PubMed ID: 23866410
    [Abstract] [Full Text] [Related]

  • 75. [Evaluation of tadalafil for the treatment of erectile dysfunction].
    Liu ZY, Sun YH.
    Zhonghua Nan Ke Xue; 2008 Apr; 14(4):377-80. PubMed ID: 18481436
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. [Efficacy and safety of two dosing regimens with Tadalafil in Spanish men with erectile dysfunction: results from the SURE study in 14 European countries].
    Martín-Morales A, Moncada Iribarren I, Cruz Navarro N, Sanz Terrada B, Cassinello Hervás A, Chan M, Casariego García-Lubén J.
    Actas Urol Esp; 2006 Sep; 30(8):791-800. PubMed ID: 17078576
    [Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80. [Tadalafil for ED after transurethral resection of the prostate: a report of 113 cases].
    Qi MJ, Cao ZG, Ja RP, Xu Z, Xu LW, Liu J, Su JH.
    Zhonghua Nan Ke Xue; 2011 Oct; 17(10):894-6. PubMed ID: 22049791
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.